[Clinical significance of adrenoreactivity in patients with some paroxysmal disorders (panic attacks and migraine)].
Akarachkova
E S
ES
Tabeeva
G R
GR
Volkova
Z I
ZI
Dlusskaia
I G
IG
Striuk
R I
RI
Veĭn
A M
AM
D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D015283:Citalopram / Q000627:therapeutic use; D039721:Diagnostic and Statistical Manual of Mental Disorders; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000175:diagnosis; D008297:Male; D008790:Metoprolol / Q000627:therapeutic use; D008881:Migraine Disorders / Q000150:complications* / Q000188:drug therapy; D016584:Panic Disorder / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology*; D010275:Parasympathetic Nervous System / Q000503:physiopathology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D011795:Surveys and Questionnaires; D013564:Sympathetic Nervous System / Q000503:physiopathology*
D000319:Adrenergic beta-Antagonists; D015283:Citalopram; D005473:Fluoxetine; D008790:Metoprolol; D017367:Selective Serotonin Reuptake Inhibitors